colorbar

Common Questions You May Have About SUSTOL

You’re bound to have questions when learning about a new treatment. Speaking with your healthcare provider is the best way to get all of the information you need. In the meantime, here are some answers to questions that you may have about SUSTOL.
Why did my healthcare provider prescribe SUSTOL?
Up to 80% of patients may experience chemotherapy-induced nausea and vomiting after receiving treatment.1 That is why you were prescribed SUSTOL.
What is SUSTOL?
SUSTOL is a prescription medicine called an “antiemetic.” SUSTOL is used in adults to help prevent the nausea and vomiting that happens right away or later with certain anti-cancer medicines (chemotherapy). It is different from other antiemetics. After being injected under the skin, it slowly releases medication to prevent nausea and vomiting.2,3
How does SUSTOL help?
SUSTOL is different from other antiemetics in that it is designed to be injected under the skin to slowly release medication over time. This design is why SUSTOL can help protect you for up to 5 days.3
When will I get SUSTOL?
Your healthcare professional will inject SUSTOL about 30 minutes before you receive your anti-cancer medicine (chemotherapy).2
What side effects can I expect with SUSTOL?
  • The most common side effects of SUSTOL include: injection site reactions, constipation, fatigue, headache, diarrhea, stomach-area (abdominal) pain, trouble sleeping or falling asleep, indigestion, dizziness, weakness, and heartburn2
  • These are not all the possible side effects of SUSTOL. Tell your healthcare provider if you have any side effect that bothers you or does not go away
Is SUSTOL expensive?
SUSTOL is covered under most insurance plans for patients who qualify. If you have commercial insurance, you may be eligible for a $0 copay,* and SUSTOL may also be provided at no cost to eligible patients who need financial assistance. For more information, call SUSTOL Connect™ Patient Services at 1-855-SUSTOL-6 (1-855-787-8656).
What if I have more questions about SUSTOL?
If you have other questions about SUSTOL, ask your healthcare professional or call SUSTOL Connect™ Patient Services at 1-855-SUSTOL-6 (1-855-787-8656).
*Limitations apply. Offer not valid as follows: (a) patients covered under Medicare, Medicaid, or any federal or state program; (b) where plan covers treatment for the patient for the entire cost of the prescription drug; or (c) towards the patient's deductible. Patients pay $0 copay per dose per 12-month calendar period. For cash-paying patients, the program will cover $150 per prescription up to $1,800 per calendar year. Eligibility is for 12 months, after which patient will need to reapply for continued assistance. Please see sustol.com for full terms and conditions. This offer expires 12-31-17.
Heron Therapeutics reserves the right, at its sole discretion, to discontinue the Patient Assistance Program or change the qualifications at any time. All patient information remains confidential. Product supply for the program depends upon availability.

Indication

SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

Important Safety Information

Contraindications

SUSTOL is contraindicated in patients with hypersensitivity to granisetron, any of the components of SUSTOL, or any other 5-HT3 receptor antagonist.

Warnings and Precautions

Injection site reactions (ISRs), including infection, bleeding, pain and tenderness, nodules, swelling, and induration, have occurred with SUSTOL. Monitor for ISRs following SUSTOL injection. Inform patients that some ISRs may occur 2 weeks or more after SUSTOL administration. In patients receiving antiplatelet agents or anticoagulants, consider the increased risk of bruising or severe hematoma prior to the use of SUSTOL.

Monitor for constipation and decreased bowel activity and consider optimizing patients’ current bowel regimens used for managing preexisting constipation. Instruct patients to seek immediate medical care if signs and symptoms of ileus occur.

Hypersensitivity reactions have been reported and may occur up to 7 days or longer following SUSTOL administration and may have an extended course. If a reaction occurs, administer appropriate treatment and monitor until signs and symptoms resolve.

Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs.

Use in Specific Populations

Avoid SUSTOL in patients with severe renal impairment. In patients with moderate renal impairment, administer SUSTOL not more frequently than once every 14 days.

Adverse Reactions

Most common adverse reactions (≥3%) are injection site reactions, constipation, fatigue, headache, diarrhea, abdominal pain, insomnia, dyspepsia, dizziness, asthenia, and gastroesophageal reflux.

For more information about SUSTOL, please see full Prescribing Information.

References:
  1. National Cancer Institute. Nausea and vomiting—for health professionals (PDR®). www.cancer.gov/about-cancer/treatment/side-effects/nausea/nausea-hp-pdq. Accessed February 28, 2016.
  2. SUSTOL [package insert]. Heron Therapeutics, Inc., Redwood City, CA; August 2016.
  3. Ottoboni T, Gelder MS, O’Boyle E. Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron. J Exp Pharmacol. 2014;6:15-21.




Indication

SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

Important Safety Information

Contraindications

SUSTOL is contraindicated in patients with hypersensitivity to granisetron, any of the components of SUSTOL, or any other 5-HT3 receptor antagonist.

Warnings and Precautions

Injection site reactions (ISRs), including infection, bleeding, pain and tenderness, nodules, swelling, and induration, have occurred with SUSTOL. Monitor for ISRs following SUSTOL injection. Inform patients that some ISRs may occur 2 weeks or more after SUSTOL administration. In patients receiving antiplatelet agents or anticoagulants, consider the increased risk of bruising or severe hematoma prior to the use of SUSTOL.

Monitor for constipation and decreased bowel activity and consider optimizing patients’ current bowel regimens used for managing preexisting constipation. Instruct patients to seek immediate medical care if signs and symptoms of ileus occur.

Hypersensitivity reactions have been reported and may occur up to 7 days or longer following SUSTOL administration and may have an extended course. If a reaction occurs, administer appropriate treatment and monitor until signs and symptoms resolve.

Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs.

Use in Specific Populations

Avoid SUSTOL in patients with severe renal impairment. In patients with moderate renal impairment, administer SUSTOL not more frequently than once every 14 days.

Adverse Reactions

Most common adverse reactions (≥3%) are injection site reactions, constipation, fatigue, headache, diarrhea, abdominal pain, insomnia, dyspepsia, dizziness, asthenia, and gastroesophageal reflux.

For more information about SUSTOL, please see full Prescribing Information.